Delphi Genetics and Eurogentec Biologics Collaborate for Antibiotic Resistance-Gene Free GMP Manufacturing
News Nov 14, 2008
Eurogentec SA and Delphi Genetics SA have signed an agreement to co-market the use of StabyDNA technology for GMP manufacturing purposes. The antibiotic resistance-gene free technology, developed and owned by Delphi Genetics allows for clone selection, plasmid stability and manufacturing of plasmids and proteins without the use of antibiotics.
Under the agreement Eurogentec will promote Delphi Genetics’ StabyDNA technology for use in GMP manufacturing on an exclusive basis. The financial terms of the agreement were not disclosed.
Philippe Gabant, CEO at Delphi Genetics said, “This collaboration will strongly contribute to the advancement of the StabyDNA technology for therapeutic applications. Eurogentec has the experience and know-how to manufacture biotherapeutics based on the StabyDNA technology and importantly has biotherapeutic manufacturing experience for all clinical phases.”
Florence Xhonneux, Biologics Business Development Manager at Eurogentec said, “ We are pleased to be collaborating with Delphi Genetics, the StabyDNA technology offers benefits in terms of GMP manufacturing and FDA and EMEA concerns about the use of antibiotics, offering real value to future sponsors of plasmid DNA clinical trials”.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE